Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

(2012) Andrea Giustina et al.   PLoS One

Elevated incidence of sleep apnoea in acromegaly—correlation to disease activity

(2012) J. Roemmler et al.   Sleep and Breathing

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

(2010) Aart-Jan van der Lely et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Current management practices for acromegaly: an international survey

(2010) A. Giustina et al.   Pituitary

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

(2009) Gherardo Mazziotti et al.   Pituitary

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

(2008) Antonio Bianchi et al.   Pituitary